The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects
Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly rel...
Saved in:
Published in | Psychopharmacologia Vol. 185; no. 1; pp. 11 - 18 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin
Springer
01.03.2006
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function.
Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p < or = 0.005; p < or = 0.035; p < or = 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p < or = 0.002; p < or = 0.05, respectively) and cortisol (p < or = 0.005; p < or = 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p < or = 0.0001) and olanzapine (p < or = 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning. |
---|---|
AbstractList | Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function.
Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p < or = 0.005; p < or = 0.035; p < or = 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p < or = 0.002; p < or = 0.05, respectively) and cortisol (p < or = 0.005; p < or = 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p < or = 0.0001) and olanzapine (p < or = 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning. Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function.RATIONALEIncreased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function.Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p < or = 0.005; p < or = 0.035; p < or = 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p < or = 0.002; p < or = 0.05, respectively) and cortisol (p < or = 0.005; p < or = 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p < or = 0.0001) and olanzapine (p < or = 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning.OBJECTIVETherefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p < or = 0.005; p < or = 0.035; p < or = 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p < or = 0.002; p < or = 0.05, respectively) and cortisol (p < or = 0.005; p < or = 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p < or = 0.0001) and olanzapine (p < or = 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning. Rationale: Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function. Objective: Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p less than or equal to 0.005; p less than or equal to 0.035; p less than or equal to 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p less than or equal to 0.002; p less than or equal to 0.05, respectively) and cortisol (p less than or equal to 0.005; p less than or equal to 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p less than or equal to 0.0001) and olanzapine (p less than or equal to 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning. Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function. Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p < or = 0.005; p < or = 0.035; p < or = 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p < or = 0.002; p < or = 0.05, respectively) and cortisol (p < or = 0.005; p < or = 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p < or = 0.0001) and olanzapine (p < or = 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning. |
Author | Wuttke, Wolfgang Huether, Gerald Meier, Andreas Jordan, Wolfgang Röher, Cornelia Cohrs, Stefan Rüther, Eckart Rodenbeck, Andrea |
Author_xml | – sequence: 1 givenname: Stefan surname: Cohrs fullname: Cohrs, Stefan – sequence: 2 givenname: Cornelia surname: Röher fullname: Röher, Cornelia – sequence: 3 givenname: Wolfgang surname: Jordan fullname: Jordan, Wolfgang – sequence: 4 givenname: Andreas surname: Meier fullname: Meier, Andreas – sequence: 5 givenname: Gerald surname: Huether fullname: Huether, Gerald – sequence: 6 givenname: Wolfgang surname: Wuttke fullname: Wuttke, Wolfgang – sequence: 7 givenname: Eckart surname: Rüther fullname: Rüther, Eckart – sequence: 8 givenname: Andrea surname: Rodenbeck fullname: Rodenbeck, Andrea |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17577386$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16432682$$D View this record in MEDLINE/PubMed |
BookMark | eNqF0k9rFDEYBvAgFbutfgAvEgQ9dfRNMvkzx7K0Vih4Wc8hk8myWWaTMclA16Of3Gx3pdCDzSUEfk_g4X0v0FmIwSH0nsAXAiC_ZgBKWAPAG6Cyax5eoQVpGW0oSHqGFgCMNYxwdY4uct5CPa1q36BzIqoSii7Qn9XGYVP2k7dmxCYUP-W93cTibcZxNOG3mXyoJAz41-yKf3xe4X4uOMSCN2aMk0t-iOMVTm6YrcPXy9XdY8DGVHyOI87OppqNAfuAN86MZbPHee63zpb8Fr1emzG7d6f7Ev28vVkt75r7H9--L6_vG9sSVRrihO3kerCqlZ2tRSwfuqHrLXfOkN4xkJIDl1T0sldMGQPGMiPalruedj27RJ-P_04p1iq56J3P1o21pItz1kIKpbhUL0IKAiTj7EVIOqpaLqHCj8_gNs4p1LaaEtUJ6MThtw8nNPc7N-gp-Z1Je_1vWBV8OgGT67TWyQTr85OTXEqmRHXk6GyKOSe3fiKgD4ujj4uj6-Low-Loh5qRzzLWF3MYWUnGj_9J_gWa-8go |
CODEN | PSYPAG |
CitedBy_id | crossref_primary_10_1155_2016_1942828 crossref_primary_10_3389_fendo_2020_00195 crossref_primary_10_3389_fpsyt_2018_00574 crossref_primary_10_1111_j_1749_6632_2009_04978_x crossref_primary_10_4103_ejpsy_ejpsy_26_21 crossref_primary_10_1016_j_pnpbp_2006_10_007 crossref_primary_10_1016_j_bbr_2019_112305 crossref_primary_10_1007_s11481_019_09857_y crossref_primary_10_1016_j_psyneuen_2015_10_014 crossref_primary_10_1016_j_schres_2019_06_023 crossref_primary_10_2512_jspm_8_566 crossref_primary_10_1016_j_neubiorev_2016_05_027 crossref_primary_10_1016_j_pnpbp_2010_10_023 crossref_primary_10_1080_08923973_2022_2037628 crossref_primary_10_3390_ijms23020908 crossref_primary_10_1017_S0954579411000289 crossref_primary_10_3389_fpsyt_2018_00501 crossref_primary_10_1016_j_ejphar_2020_172978 crossref_primary_10_3389_fpsyt_2019_00834 crossref_primary_10_1016_j_psyneuen_2012_12_025 crossref_primary_10_1038_sj_npp_1301395 crossref_primary_10_1016_j_pnpbp_2020_110162 crossref_primary_10_1097_JCP_0b013e31829e8333 crossref_primary_10_1002_14651858_CD006995_pub2 crossref_primary_10_3390_jcm10215204 crossref_primary_10_1016_j_psychres_2022_114762 crossref_primary_10_1016_j_ejphar_2008_06_105 crossref_primary_10_1016_j_schres_2007_01_022 crossref_primary_10_1016_j_brainres_2013_06_034 crossref_primary_10_1080_15622975_2018_1433878 crossref_primary_10_1016_j_nbd_2010_04_017 crossref_primary_10_1016_j_psyneuen_2011_08_013 crossref_primary_10_1177_0269881108097715 crossref_primary_10_30773_pi_2020_0269 crossref_primary_10_1016_j_psyneuen_2016_11_036 crossref_primary_10_1016_j_schres_2015_01_010 crossref_primary_10_1146_annurev_clinpsy_4_022007_141248 crossref_primary_10_1590_1516_4446_2014_1634 crossref_primary_10_1016_j_psyneuen_2018_06_007 crossref_primary_10_1517_13543784_2013_782392 crossref_primary_10_3389_fphys_2021_674550 crossref_primary_10_1517_14656566_8_9_1211 crossref_primary_10_1016_j_pscychresns_2011_11_008 crossref_primary_10_1097_JCP_0b013e31814f4d82 crossref_primary_10_1016_j_jand_2021_07_016 crossref_primary_10_1016_j_npep_2008_06_002 crossref_primary_10_3928_00485713_20090625_02 crossref_primary_10_3389_fcell_2022_880544 crossref_primary_10_1016_j_prp_2013_09_010 crossref_primary_10_1007_s11102_008_0114_6 crossref_primary_10_3390_ph16081097 crossref_primary_10_1016_j_psyneuen_2008_11_008 crossref_primary_10_1016_j_bionps_2020_100011 crossref_primary_10_3389_fnut_2022_943998 crossref_primary_10_1586_14737175_7_7_841 crossref_primary_10_1016_j_schres_2016_03_039 crossref_primary_10_1016_j_bionps_2024_100098 crossref_primary_10_1016_j_jpsychires_2014_01_013 crossref_primary_10_1016_j_psychres_2013_12_016 crossref_primary_10_1016_j_neuropharm_2011_07_001 crossref_primary_10_1159_000437437 crossref_primary_10_1016_j_psyneuen_2019_03_014 crossref_primary_10_1016_j_euroneuro_2014_10_005 crossref_primary_10_2174_1570159X21666230322145049 crossref_primary_10_1016_j_neubiorev_2017_12_012 crossref_primary_10_2147_NDT_S306458 crossref_primary_10_1017_S003329172300380X crossref_primary_10_1080_10253890_2016_1193146 crossref_primary_10_1007_s12031_015_0625_3 crossref_primary_10_1016_j_neubiorev_2016_12_013 crossref_primary_10_1111_bcpt_13323 crossref_primary_10_1016_j_schres_2009_05_008 crossref_primary_10_1142_S0219635214500253 crossref_primary_10_1007_s00213_019_05442_6 crossref_primary_10_1016_j_psyneuen_2008_09_004 crossref_primary_10_1016_j_heliyon_2023_e21173 crossref_primary_10_1016_j_jpsychires_2016_06_014 crossref_primary_10_1097_JCP_0b013e31819b95fc crossref_primary_10_1080_14789450_2017_1375857 crossref_primary_10_1155_2020_9124520 crossref_primary_10_1111_j_1365_2788_2012_01557_x crossref_primary_10_1016_j_psyneuen_2016_01_021 crossref_primary_10_1038_tp_2017_94 crossref_primary_10_1016_j_jpsychires_2014_02_022 crossref_primary_10_1097_YIC_0b013e32801182e6 crossref_primary_10_1016_j_psyneuen_2012_06_002 crossref_primary_10_1016_j_schres_2009_10_005 crossref_primary_10_1016_j_pnpbp_2008_09_009 crossref_primary_10_1016_j_schres_2017_04_035 crossref_primary_10_3389_fpsyt_2019_00974 crossref_primary_10_1016_j_biopsycho_2018_08_016 crossref_primary_10_4158_EP12415_CR crossref_primary_10_1177_1359786810385491 crossref_primary_10_1517_13543784_2010_515586 crossref_primary_10_1124_jpet_113_205864 crossref_primary_10_5937_mp69_17304 crossref_primary_10_1111_j_1365_2826_2006_01516_x crossref_primary_10_15406_jpcpy_2015_02_00068 crossref_primary_10_1016_j_jad_2020_07_071 crossref_primary_10_1016_j_pnpbp_2010_05_021 crossref_primary_10_1111_j_1601_5215_2008_00340_x crossref_primary_10_1177_0269881109103090 crossref_primary_10_1016_j_schres_2009_08_013 crossref_primary_10_3390_ph13100322 crossref_primary_10_1186_s40360_017_0171_4 crossref_primary_10_1586_ern_09_52 crossref_primary_10_1007_s00213_006_0452_x crossref_primary_10_1002_wps_20144 crossref_primary_10_1016_j_psyneuen_2014_07_013 crossref_primary_10_1111_pcn_12093 |
Cites_doi | 10.1023/A:1009986822146 10.1007/BF02245012 10.1016/S0920-9964(01)00268-7 10.1001/archpsyc.1978.01770250110011 10.1093/schbul/20.2.327 10.1001/archpsyc.1976.01770030003001 10.1176/appi.ajp.158.1.131 10.1001/archpsyc.60.11.1079 10.4088/JCP.v65n0109 10.1007/BF00427446 10.1007/BF00442554 10.1016/0024-3205(86)90656-9 10.1016/S0893-133X(00)00159-7 10.1007/BF00735811 10.1016/0165-1781(91)90013-F 10.1097/00004714-199604000-00008 10.1016/S0306-4530(99)00029-3 10.1007/BF00432027 10.1007/s00213-002-1356-z 10.1001/archpsyc.57.6.553 10.1111/j.1600-0404.1993.tb04075.x 10.1016/S0024-3205(00)00911-5 10.1176/appi.ajp.159.1.133 10.1176/appi.books.9798894550442.lg05 10.1517/14656566.3.10.1381 10.1210/jcem-41-5-981 10.1016/S0920-9964(01)00367-X 10.1016/0278-5846(85)90082-X 10.1016/0278-5846(95)00105-5 10.1007/BF02246165 10.1111/j.1365-2125.1995.tb04403.x 10.1097/00004714-200112000-00006 10.1007/BF00546704 10.1007/BF02244242 10.1016/S0278-5846(98)00064-5 10.1016/S0006-3223(00)01052-0 10.1139/y00-098 10.2165/00023210-200317110-00003 10.1111/j.1365-2265.1975.tb01526.x 10.1038/npp.1994.1 10.1097/00005053-198208000-00004 10.1097/00006842-199909000-00011 10.1001/archpsyc.57.3.249 10.3109/15622970209150617 10.1192/bjp.182.3.199 10.1055/s-2007-979503 10.1016/0022-3956(94)90004-3 10.1016/S0006-3223(03)00473-6 10.1016/S0924-977X(99)00017-6 10.1016/S0022-3956(01)00018-8 10.1016/0028-3908(84)90078-9 10.1007/s00213-002-1057-7 10.1176/appi.ajp.159.6.1018 10.1016/S0924-977X(99)00040-1 10.1016/0306-4530(86)90008-9 10.1055/s-2007-979502 10.1111/j.1365-2265.1983.tb02986.x 10.1038/266639a0 10.1176/appi.ajp.159.9.1608 |
ContentType | Journal Article |
Copyright | 2006 INIST-CNRS Springer-Verlag 2006 |
Copyright_xml | – notice: 2006 INIST-CNRS – notice: Springer-Verlag 2006 |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QG 7QR 7RV 7TK 7X7 7XB 88E 88G 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ K9. KB0 M0S M1P M2M NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 |
DOI | 10.1007/s00213-005-0279-x |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Animal Behavior Abstracts Chemoreception Abstracts Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Psychology Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition Animal Behavior Abstracts ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Neurosciences Abstracts ProQuest One Psychology Neurosciences Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central (New) url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1432-2072 |
EndPage | 18 |
ExternalDocumentID | 993072191 16432682 17577386 10_1007_s00213_005_0279_x |
Genre | Randomized Controlled Trial Journal Article Comparative Study |
GroupedDBID | .55 3SX 40D 40E 95. 95~ AAYXX ABMNI AGWIL ALMA_UNASSIGNED_HOLDINGS CITATION KOW N2Q R9- RHV SBY SOJ X7M ~EX -4W -BR IQODW CGR CUY CVF ECM EIF NPM 3V. 7QG 7QR 7RV 7TK 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GNUQQ K9. M1P M2M NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 |
ID | FETCH-LOGICAL-c418t-1e6c97fdc8479c048c5d9d9bc5eea1be3077505726b7b838aa0ac3a6445eb29b3 |
IEDL.DBID | 7X7 |
ISSN | 0033-3158 |
IngestDate | Fri Jul 11 11:56:40 EDT 2025 Thu Jul 10 18:14:49 EDT 2025 Fri Jul 11 08:27:58 EDT 2025 Sun Aug 17 23:55:40 EDT 2025 Sat Sep 28 07:44:48 EDT 2024 Tue Sep 20 18:53:38 EDT 2022 Thu Apr 24 22:59:31 EDT 2025 Tue Jul 01 00:40:02 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Atypical antipsychotic Olanzapine Neuroleptic Psychotropic Serotonine receptor Haloperidol Hydrocortisone Glucocorticoid Dibenzothiazepine derivatives Quetiapine Human Corticosteroid Healthy subject Steroid hormone Secretion Dopamine antagonist Serotonin antagonist Hypnotic Butyrophenone derivatives Thienobenzodiazepine derivatives Chemotherapy D2 Dopamine receptor Adrenocorticotropic hormone Tranquillizer Adenohypophyseal hormone Adrenal hormone |
Language | English |
License | http://www.springer.com/tdm CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c418t-1e6c97fdc8479c048c5d9d9bc5eea1be3077505726b7b838aa0ac3a6445eb29b3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
PMID | 16432682 |
PQID | 218960963 |
PQPubID | 23462 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_67688578 proquest_miscellaneous_20607353 proquest_miscellaneous_19284570 proquest_journals_218960963 pubmed_primary_16432682 pascalfrancis_primary_17577386 crossref_primary_10_1007_s00213_005_0279_x crossref_citationtrail_10_1007_s00213_005_0279_x |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2006-03-01 |
PublicationDateYYYYMMDD | 2006-03-01 |
PublicationDate_xml | – month: 03 year: 2006 text: 2006-03-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Berlin |
PublicationPlace_xml | – name: Berlin – name: Germany – name: Heidelberg |
PublicationTitle | Psychopharmacologia |
PublicationTitleAlternate | Psychopharmacology (Berl) |
PublicationYear | 2006 |
Publisher | Springer Springer Nature B.V |
Publisher_xml | – name: Springer – name: Springer Nature B.V |
References | H Wetzel (279_CR66) 1994; 28 DI Velligan (279_CR61) 2002; 53 S Damluji al (279_CR3) 1993; 7 CS Wilcox (279_CR69) 1975; 4 ES Brown (279_CR15) 2004; 55 B Allolio (279_CR6) 1987; 16 RT Rubin (279_CR50) 1976; 47 HY Meltzer (279_CR42) 1976; 33 F Holsboer (279_CR29) 2000; 23 J Volavka (279_CR62) 2004; 65 AC Altamura (279_CR7) 1999; 10 M Markianos (279_CR39) 1999; 9 C Barbieri (279_CR10) 1984; 26 Y Shirayama (279_CR56) 2002; 58 DJ Walder (279_CR64) 2000; 48 EJ Marco (279_CR38) 2002; 3 M Alexiadis (279_CR4) 2002; 159 J Tuomisto (279_CR59) 1985; 37 S Cohrs (279_CR17) 2004; 174 R Collu (279_CR18) 1975; 41 C Schule (279_CR52) 2003; 166 D Jezova Repcekova (279_CR31) 1979; 17 M Harrow (279_CR26) 1994; 20 JP Seibyl (279_CR54) 1991; 38 G Laakmann (279_CR36) 1999; 24 JR Calabrese (279_CR16) 2004 M Mauri (279_CR40) 1993; 87 HY Meltzer (279_CR41) 1989; 99 RL Borison (279_CR13) 1996; 16 E Richelson (279_CR49) 2000; 68 SC Schulz (279_CR2) 2002; 63 RC Shelton (279_CR55) 2001; 158 PH Gruen (279_CR24) 1978; 35 RM Bilder (279_CR12) 2002; 159 MM Murburg (279_CR45) 1993; 77 279_CR71 G Laakmann (279_CR34) 1984; 84 A Wieck (279_CR68) 2003; 182 H Wetzel (279_CR67) 1995; 119 J Hatzimanolis (279_CR27) 1998; 22 JI Nurnberger Jr (279_CR47) 1984; 84 C Bahr von (279_CR63) 1991; 103 CB Nemeroff (279_CR46) 1997; 58 TE Seeman (279_CR53) 1997; 82 P Koning de (279_CR20) 1995; 39 MM Murburg (279_CR44) 1986; 39 A Breier (279_CR14) 1994; 10 FE Scheepers (279_CR51) 2001; 21 S Kapur (279_CR33) 2000; 57 AM Ghadirian (279_CR22) 1982; 170 T Baptista (279_CR9) 1997; 30 M Hornig (279_CR30) 2003 G Langer (279_CR37) 1977; 266 A Weizman (279_CR65) 1985; 9 JK Belanoff (279_CR11) 2001; 35 T Baptista (279_CR8) 1997; 30 N Sonino (279_CR57) 2000; 3 OM Wolkowitz (279_CR70) 1999; 61 SE Purdon (279_CR48) 2000; 57 HJ Möller (279_CR43) 2003; 17 PJ Goodnick (279_CR23) 2002; 3 J Hennig (279_CR28) 1995; 19 MB Hamner (279_CR25) 1996; 32 G Laakmann (279_CR35) 1986; 11 M Tohen (279_CR58) 2003; 60 B Allolio (279_CR5) 1983; 19 RS Kahn (279_CR32) 1993; 112 P Turrone (279_CR60) 2002; 159 V Contesse (279_CR19) 2000; 78 W Abi Saab (279_CR1) 2002; 162 RW Fuller (279_CR21) 1984; 23 6124580 - J Nerv Ment Dis. 1982 Aug;170(8):463-7 193037 - Nature. 1977 Apr 14;266(5603):639-40 12562145 - J Clin Psychiatry. 2002;63 Suppl 13:32-8 8927658 - Psychopharmacol Bull. 1996;32(1):107-10 10711911 - Arch Gen Psychiatry. 2000 Mar;57(3):249-58 6143669 - Eur J Clin Pharmacol. 1984;26(1):29-32 165915 - Clin Endocrinol (Oxf). 1975 Mar;4(2):191-8 14735295 - Psychopharmacology (Berl). 2004 Jul;174(3):414-20 8179790 - Neuropsychopharmacology. 1994 Feb;10(1):1-7 9829289 - Prog Neuropsychopharmacol Biol Psychiatry. 1998 Oct;22(7):1077-85 11763004 - J Clin Psychopharmacol. 2001 Dec;21(6):575-82 8387773 - Baillieres Clin Endocrinol Metab. 1993 Apr;7(2):355-92 1273208 - Psychopharmacologia. 1976 May 28;47(2):135-40 14706419 - Biol Psychiatry. 2004 Jan 1;55(1):1-9 6093182 - Psychopharmacology (Berl). 1984;84(1):66-70 7831445 - Psychopharmacology (Berl). 1993;112(1 Suppl):S90-4 12042192 - Am J Psychiatry. 2002 Jun;159(6):1018-28 1259521 - Arch Gen Psychiatry. 1976 Mar;33(3):279-86 1676524 - Psychopharmacology (Berl). 1991;103(4):443-8 8424312 - Acta Neurol Scand. 1993 Jan;87(1):52-5 11461709 - J Psychiatr Res. 2001 May-Jun;35(3):127-45 11738537 - Schizophr Res. 2002 Jan 15;53(3):239-48 11137052 - Biol Psychiatry. 2000 Dec 15;48(12):1121-32 11149386 - Can J Physiol Pharmacol. 2000 Dec;78(12):967-83 10839333 - Arch Gen Psychiatry. 2000 Jun;57(6):553-9 8588059 - Prog Neuropsychopharmacol Biol Psychiatry. 1995 Jul;19(4):603-14 12202292 - Am J Psychiatry. 2002 Sep;159(9):1608-9 11141696 - Pituitary. 2000 Oct;3(2):55-9 7897617 - J Psychiatr Res. 1994 Sep-Oct;28(5):461-73 4001434 - Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(2):193-8 10451911 - Psychoneuroendocrinology. 1999 Oct;24(7):769-84 23087 - Arch Gen Psychiatry. 1978 Jan;35(1):108-16 14609883 - Arch Gen Psychiatry. 2003 Nov;60(11):1079-88 12552362 - Psychopharmacology (Berl). 2003 Mar;166(3):271-5 1754635 - Psychiatry Res. 1991 Sep;38(3):227-36 8690831 - J Clin Psychopharmacol. 1996 Apr;16(2):158-69 171278 - J Clin Endocrinol Metab. 1975 Nov;41(5):981-4 6527743 - Neuropharmacology. 1984 Dec;23(12A):1389-94 11132243 - Life Sci. 2000 Nov 24;68(1):29-39 11772702 - Am J Psychiatry. 2002 Jan;159(1):133-5 11136647 - Am J Psychiatry. 2001 Jan;158(1):131-4 2832287 - Horm Metab Res Suppl. 1987;16:36-8 8408451 - J Clin Endocrinol Metab. 1993 Oct;77(4):1033-40 7756102 - Br J Clin Pharmacol. 1995 Jan;39(1):7-14 12478881 - World J Biol Psychiatry. 2002 Jul;3(3):156-61 9442547 - Pharmacopsychiatry. 1997 Nov;30(6):250-5 2869509 - Pharmacol Rev. 1985 Sep;37(3):249-332 6239300 - Psychopharmacology (Berl). 1984;84(2):200-4 2682729 - Psychopharmacology (Berl). 1989;99 Suppl:S18-27 12107618 - Psychopharmacology (Berl). 2002 Jun;162(1):55-62 14744169 - J Clin Psychiatry. 2004 Jan;65(1):57-61 10625122 - Eur Neuropsychopharmacol. 1999 Dec;9(6):533-6 10647089 - Eur Neuropsychopharmacol. 1999 Dec;10(1):1-4 7659771 - Psychopharmacology (Berl). 1995 May;119(2):231-8 9442548 - Pharmacopsychiatry. 1997 Nov;30(6):256-62 12387684 - Expert Opin Pharmacother. 2002 Oct;3(10):1381-91 10511017 - Psychosom Med. 1999 Sep-Oct;61(5):698-711 2942747 - Life Sci. 1986 Jul 28;39(4):373-81 11027914 - Neuropsychopharmacology. 2000 Nov;23(5):477-501 9253318 - J Clin Endocrinol Metab. 1997 Aug;82(8):2458-65 12921492 - CNS Drugs. 2003;17(11):793-823 422303 - Int J Clin Pharmacol Biopharm. 1979 Feb;17(2):64-7 12611781 - Br J Psychiatry. 2003 Mar;182:199-204 6309434 - Clin Endocrinol (Oxf). 1983 Aug;19(2):239-45 3031718 - Psychoneuroendocrinology. 1986;11(4):475-89 9265916 - J Clin Psychiatry. 1997;58 Suppl 10:45-9 8085135 - Schizophr Bull. 1994;20(2):327-38 12363392 - Schizophr Res. 2002 Nov 1;58(1):69-74 |
References_xml | – volume: 3 start-page: 55 year: 2000 ident: 279_CR57 publication-title: Pituitary doi: 10.1023/A:1009986822146 – volume: 37 start-page: 249 year: 1985 ident: 279_CR59 publication-title: Pharmacol Rev – volume: 112 start-page: S90 year: 1993 ident: 279_CR32 publication-title: Psychopharmacology (Berl) doi: 10.1007/BF02245012 – volume: 53 start-page: 239 year: 2002 ident: 279_CR61 publication-title: Schizophr Res doi: 10.1016/S0920-9964(01)00268-7 – volume: 35 start-page: 108 year: 1978 ident: 279_CR24 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1978.01770250110011 – ident: 279_CR71 – volume: 20 start-page: 327 year: 1994 ident: 279_CR26 publication-title: Schizophr Bull doi: 10.1093/schbul/20.2.327 – volume: 33 start-page: 279 year: 1976 ident: 279_CR42 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1976.01770030003001 – volume: 158 start-page: 131 year: 2001 ident: 279_CR55 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.158.1.131 – volume: 60 start-page: 1079 year: 2003 ident: 279_CR58 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.60.11.1079 – volume: 65 start-page: 57 year: 2004 ident: 279_CR62 publication-title: J Clin Psychiatry doi: 10.4088/JCP.v65n0109 – volume: 84 start-page: 200 year: 1984 ident: 279_CR47 publication-title: Psychopharmacology (Berl) doi: 10.1007/BF00427446 – volume: 99 start-page: S18 issue: Suppl year: 1989 ident: 279_CR41 publication-title: Psychopharmacology (Berl) doi: 10.1007/BF00442554 – volume: 39 start-page: 373 year: 1986 ident: 279_CR44 publication-title: Life Sci doi: 10.1016/0024-3205(86)90656-9 – volume: 23 start-page: 477 year: 2000 ident: 279_CR29 publication-title: Neuropsychopharmacology doi: 10.1016/S0893-133X(00)00159-7 – volume: 47 start-page: 135 year: 1976 ident: 279_CR50 publication-title: Psychopharmacologia doi: 10.1007/BF00735811 – volume: 38 start-page: 227 year: 1991 ident: 279_CR54 publication-title: Psychiatry Res doi: 10.1016/0165-1781(91)90013-F – volume: 16 start-page: 158 year: 1996 ident: 279_CR13 publication-title: J Clin Psychopharmacol doi: 10.1097/00004714-199604000-00008 – volume: 24 start-page: 769 year: 1999 ident: 279_CR36 publication-title: Psychoneuroendocrinology doi: 10.1016/S0306-4530(99)00029-3 – volume: 77 start-page: 1033 year: 1993 ident: 279_CR45 publication-title: J Clin Endocrinol Metab – volume: 84 start-page: 66 year: 1984 ident: 279_CR34 publication-title: Psychopharmacology (Berl) doi: 10.1007/BF00432027 – volume: 166 start-page: 271 year: 2003 ident: 279_CR52 publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-002-1356-z – volume: 57 start-page: 553 year: 2000 ident: 279_CR33 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.57.6.553 – volume: 87 start-page: 52 year: 1993 ident: 279_CR40 publication-title: Acta Neurol Scand doi: 10.1111/j.1600-0404.1993.tb04075.x – volume: 68 start-page: 29 year: 2000 ident: 279_CR49 publication-title: Life Sci doi: 10.1016/S0024-3205(00)00911-5 – volume: 159 start-page: 133 year: 2002 ident: 279_CR60 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.159.1.133 – volume: 32 start-page: 107 year: 1996 ident: 279_CR25 publication-title: Psychopharmacol Bull – start-page: 107 volume-title: Psychoneuroendocrinology. The Scientific basis of clinical practice year: 2003 ident: 279_CR30 doi: 10.1176/appi.books.9798894550442.lg05 – volume: 3 start-page: 1381 year: 2002 ident: 279_CR23 publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.3.10.1381 – volume: 41 start-page: 981 year: 1975 ident: 279_CR18 publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem-41-5-981 – volume: 58 start-page: 69 year: 2002 ident: 279_CR56 publication-title: Schizophr Res doi: 10.1016/S0920-9964(01)00367-X – volume: 9 start-page: 193 year: 1985 ident: 279_CR65 publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/0278-5846(85)90082-X – volume: 19 start-page: 603 year: 1995 ident: 279_CR28 publication-title: Prog Neuro-Psychopharmacol Biol Psychiatry doi: 10.1016/0278-5846(95)00105-5 – volume: 119 start-page: 231 year: 1995 ident: 279_CR67 publication-title: Psychopharmacology (Berl) doi: 10.1007/BF02246165 – volume: 39 start-page: 7 year: 1995 ident: 279_CR20 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1995.tb04403.x – volume: 21 start-page: 575 year: 2001 ident: 279_CR51 publication-title: J Clin Psychopharmacol doi: 10.1097/00004714-200112000-00006 – volume: 26 start-page: 29 year: 1984 ident: 279_CR10 publication-title: Eur J Clin Pharmacol doi: 10.1007/BF00546704 – volume: 103 start-page: 443 year: 1991 ident: 279_CR63 publication-title: Psychopharmacology (Berl) doi: 10.1007/BF02244242 – start-page: 284 volume-title: American psychiatric association 157th annual meeting year: 2004 ident: 279_CR16 – volume: 22 start-page: 1077 year: 1998 ident: 279_CR27 publication-title: Prog Neuro-Psychopharmacol Biol Psychiatry doi: 10.1016/S0278-5846(98)00064-5 – volume: 48 start-page: 1121 year: 2000 ident: 279_CR64 publication-title: Biol Psychiatry doi: 10.1016/S0006-3223(00)01052-0 – volume: 7 start-page: 355 year: 1993 ident: 279_CR3 publication-title: Clin Endocrinol Metab – volume: 78 start-page: 967 year: 2000 ident: 279_CR19 publication-title: Can J Physiol Pharmacol doi: 10.1139/y00-098 – volume: 17 start-page: 793 year: 2003 ident: 279_CR43 publication-title: CNS Drugs doi: 10.2165/00023210-200317110-00003 – volume: 4 start-page: 191 year: 1975 ident: 279_CR69 publication-title: Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.1975.tb01526.x – volume: 10 start-page: 1 year: 1994 ident: 279_CR14 publication-title: Neuropsychopharmacology doi: 10.1038/npp.1994.1 – volume: 170 start-page: 463 year: 1982 ident: 279_CR22 publication-title: J Nerv Ment Dis doi: 10.1097/00005053-198208000-00004 – volume: 61 start-page: 698 year: 1999 ident: 279_CR70 publication-title: Psychosom Med doi: 10.1097/00006842-199909000-00011 – volume: 57 start-page: 249 year: 2000 ident: 279_CR48 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.57.3.249 – volume: 17 start-page: 64 year: 1979 ident: 279_CR31 publication-title: Int J Clin Pharmacol Biopharm – volume: 82 start-page: 2458 year: 1997 ident: 279_CR53 publication-title: J Clin Endocrinol Metab – volume: 3 start-page: 156 year: 2002 ident: 279_CR38 publication-title: World J Biol Psychiatry doi: 10.3109/15622970209150617 – volume: 182 start-page: 199 year: 2003 ident: 279_CR68 publication-title: Br J Psychiatry doi: 10.1192/bjp.182.3.199 – volume: 16 start-page: 36 year: 1987 ident: 279_CR6 publication-title: Horm Metab Res Suppl – volume: 30 start-page: 256 year: 1997 ident: 279_CR9 publication-title: Pharmacopsychiatry doi: 10.1055/s-2007-979503 – volume: 28 start-page: 461 year: 1994 ident: 279_CR66 publication-title: J Psychiatr Res doi: 10.1016/0022-3956(94)90004-3 – volume: 58 start-page: 45 issue: Suppl 10 year: 1997 ident: 279_CR46 publication-title: J Clin Psychiatry – volume: 63 start-page: 32 year: 2002 ident: 279_CR2 publication-title: J Clin Psychiatry – volume: 55 start-page: 1 year: 2004 ident: 279_CR15 publication-title: Biol Psychiatry doi: 10.1016/S0006-3223(03)00473-6 – volume: 174 start-page: 414 year: 2004 ident: 279_CR17 publication-title: Psychopharmacology (Berl) – volume: 10 start-page: 1 year: 1999 ident: 279_CR7 publication-title: Eur Neuropsychopharmacol doi: 10.1016/S0924-977X(99)00017-6 – volume: 35 start-page: 127 year: 2001 ident: 279_CR11 publication-title: J Psychiatr Res doi: 10.1016/S0022-3956(01)00018-8 – volume: 23 start-page: 1389 year: 1984 ident: 279_CR21 publication-title: Neuropharmacology doi: 10.1016/0028-3908(84)90078-9 – volume: 162 start-page: 55 year: 2002 ident: 279_CR1 publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-002-1057-7 – volume: 159 start-page: 1018 year: 2002 ident: 279_CR12 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.159.6.1018 – volume: 9 start-page: 533 year: 1999 ident: 279_CR39 publication-title: Eur Neuropsychopharmacol doi: 10.1016/S0924-977X(99)00040-1 – volume: 11 start-page: 475 year: 1986 ident: 279_CR35 publication-title: Psychoneuroendocrinology doi: 10.1016/0306-4530(86)90008-9 – volume: 30 start-page: 250 year: 1997 ident: 279_CR8 publication-title: Pharmacopsychiatry doi: 10.1055/s-2007-979502 – volume: 19 start-page: 239 year: 1983 ident: 279_CR5 publication-title: Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.1983.tb02986.x – volume: 266 start-page: 639 year: 1977 ident: 279_CR37 publication-title: Nature doi: 10.1038/266639a0 – volume: 159 start-page: 1608 year: 2002 ident: 279_CR4 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.159.9.1608 – reference: 2942747 - Life Sci. 1986 Jul 28;39(4):373-81 – reference: 10839333 - Arch Gen Psychiatry. 2000 Jun;57(6):553-9 – reference: 8387773 - Baillieres Clin Endocrinol Metab. 1993 Apr;7(2):355-92 – reference: 8588059 - Prog Neuropsychopharmacol Biol Psychiatry. 1995 Jul;19(4):603-14 – reference: 9442547 - Pharmacopsychiatry. 1997 Nov;30(6):250-5 – reference: 7756102 - Br J Clin Pharmacol. 1995 Jan;39(1):7-14 – reference: 4001434 - Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(2):193-8 – reference: 8424312 - Acta Neurol Scand. 1993 Jan;87(1):52-5 – reference: 3031718 - Psychoneuroendocrinology. 1986;11(4):475-89 – reference: 171278 - J Clin Endocrinol Metab. 1975 Nov;41(5):981-4 – reference: 2869509 - Pharmacol Rev. 1985 Sep;37(3):249-332 – reference: 6309434 - Clin Endocrinol (Oxf). 1983 Aug;19(2):239-45 – reference: 14735295 - Psychopharmacology (Berl). 2004 Jul;174(3):414-20 – reference: 11738537 - Schizophr Res. 2002 Jan 15;53(3):239-48 – reference: 11136647 - Am J Psychiatry. 2001 Jan;158(1):131-4 – reference: 10711911 - Arch Gen Psychiatry. 2000 Mar;57(3):249-58 – reference: 10511017 - Psychosom Med. 1999 Sep-Oct;61(5):698-711 – reference: 7831445 - Psychopharmacology (Berl). 1993;112(1 Suppl):S90-4 – reference: 14744169 - J Clin Psychiatry. 2004 Jan;65(1):57-61 – reference: 12387684 - Expert Opin Pharmacother. 2002 Oct;3(10):1381-91 – reference: 6239300 - Psychopharmacology (Berl). 1984;84(2):200-4 – reference: 2682729 - Psychopharmacology (Berl). 1989;99 Suppl:S18-27 – reference: 1676524 - Psychopharmacology (Berl). 1991;103(4):443-8 – reference: 422303 - Int J Clin Pharmacol Biopharm. 1979 Feb;17(2):64-7 – reference: 14609883 - Arch Gen Psychiatry. 2003 Nov;60(11):1079-88 – reference: 11772702 - Am J Psychiatry. 2002 Jan;159(1):133-5 – reference: 11137052 - Biol Psychiatry. 2000 Dec 15;48(12):1121-32 – reference: 12562145 - J Clin Psychiatry. 2002;63 Suppl 13:32-8 – reference: 23087 - Arch Gen Psychiatry. 1978 Jan;35(1):108-16 – reference: 12202292 - Am J Psychiatry. 2002 Sep;159(9):1608-9 – reference: 7897617 - J Psychiatr Res. 1994 Sep-Oct;28(5):461-73 – reference: 9253318 - J Clin Endocrinol Metab. 1997 Aug;82(8):2458-65 – reference: 11149386 - Can J Physiol Pharmacol. 2000 Dec;78(12):967-83 – reference: 12042192 - Am J Psychiatry. 2002 Jun;159(6):1018-28 – reference: 8408451 - J Clin Endocrinol Metab. 1993 Oct;77(4):1033-40 – reference: 6527743 - Neuropharmacology. 1984 Dec;23(12A):1389-94 – reference: 1754635 - Psychiatry Res. 1991 Sep;38(3):227-36 – reference: 11141696 - Pituitary. 2000 Oct;3(2):55-9 – reference: 14706419 - Biol Psychiatry. 2004 Jan 1;55(1):1-9 – reference: 12478881 - World J Biol Psychiatry. 2002 Jul;3(3):156-61 – reference: 11763004 - J Clin Psychopharmacol. 2001 Dec;21(6):575-82 – reference: 11461709 - J Psychiatr Res. 2001 May-Jun;35(3):127-45 – reference: 11132243 - Life Sci. 2000 Nov 24;68(1):29-39 – reference: 12363392 - Schizophr Res. 2002 Nov 1;58(1):69-74 – reference: 6143669 - Eur J Clin Pharmacol. 1984;26(1):29-32 – reference: 12552362 - Psychopharmacology (Berl). 2003 Mar;166(3):271-5 – reference: 8085135 - Schizophr Bull. 1994;20(2):327-38 – reference: 6124580 - J Nerv Ment Dis. 1982 Aug;170(8):463-7 – reference: 12921492 - CNS Drugs. 2003;17(11):793-823 – reference: 1273208 - Psychopharmacologia. 1976 May 28;47(2):135-40 – reference: 9442548 - Pharmacopsychiatry. 1997 Nov;30(6):256-62 – reference: 165915 - Clin Endocrinol (Oxf). 1975 Mar;4(2):191-8 – reference: 1259521 - Arch Gen Psychiatry. 1976 Mar;33(3):279-86 – reference: 10647089 - Eur Neuropsychopharmacol. 1999 Dec;10(1):1-4 – reference: 8179790 - Neuropsychopharmacology. 1994 Feb;10(1):1-7 – reference: 10625122 - Eur Neuropsychopharmacol. 1999 Dec;9(6):533-6 – reference: 11027914 - Neuropsychopharmacology. 2000 Nov;23(5):477-501 – reference: 7659771 - Psychopharmacology (Berl). 1995 May;119(2):231-8 – reference: 12107618 - Psychopharmacology (Berl). 2002 Jun;162(1):55-62 – reference: 12611781 - Br J Psychiatry. 2003 Mar;182:199-204 – reference: 193037 - Nature. 1977 Apr 14;266(5603):639-40 – reference: 9829289 - Prog Neuropsychopharmacol Biol Psychiatry. 1998 Oct;22(7):1077-85 – reference: 9265916 - J Clin Psychiatry. 1997;58 Suppl 10:45-9 – reference: 8690831 - J Clin Psychopharmacol. 1996 Apr;16(2):158-69 – reference: 10451911 - Psychoneuroendocrinology. 1999 Oct;24(7):769-84 – reference: 2832287 - Horm Metab Res Suppl. 1987;16:36-8 – reference: 8927658 - Psychopharmacol Bull. 1996;32(1):107-10 – reference: 6093182 - Psychopharmacology (Berl). 1984;84(1):66-70 |
SSID | ssj0000484 ssj0068394 |
Score | 2.2076533 |
Snippet | Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia.... Rationale: Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and... |
SourceID | proquest pubmed pascalfrancis crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 11 |
SubjectTerms | Adrenocorticotropic Hormone - blood Adult Antipsychotic Agents - pharmacology Antipsychotics Benzodiazepines - pharmacology Biological and medical sciences Cross-Over Studies Dibenzothiazepines - pharmacology Double-Blind Method Haloperidol - pharmacology Humans Hydrocortisone - blood Hypothalamo-Hypophyseal System - drug effects Male Medical sciences Neuropharmacology Pharmacology. Drug treatments Pituitary-Adrenal System - drug effects Prolactin - blood Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Quetiapine Fumarate |
Title | The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects |
URI | https://www.ncbi.nlm.nih.gov/pubmed/16432682 https://www.proquest.com/docview/218960963 https://www.proquest.com/docview/19284570 https://www.proquest.com/docview/20607353 https://www.proquest.com/docview/67688578 |
Volume | 185 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swED-2FsagjK378rplehh9GDHzl2T5aSSlIQwawkghb0aSZRYItlc70PRxf_nubCehD82TEZKM0El3P0l3vwP4JrPcj0NEbrlRxo0SqVyVR56bRTpXPNTatjyzNzMxvY1-Lfmy982pe7fKnU5sFXVWGroj_4GmiMjRRPiz-utS0ih6XO0zaDyHU2IuI4-ueBkfFHFEMZhdQSAQ6BiZQ4on43L3wum1hKIB5TggN7YgTtz7RzbqrFI1Tlfe5bl4Goi2BmnyGl71SJKNOtG_gWe2OIcXN_1b-TlczjtW6u2QLQ5BVvWQXbL5ga96-xb-YTVTzbYieTGc6VUfmoWtGZ58iwdV4R-xJmM4JFQJVBwyvWlYUTbsj1qXxJecleshuyMqWMtGV4tp2wEPt80K1zerCZ_SKmCrgnXRl1tWbzTdA9Xv4HZyvbiaun1qBtdEvmxc3wqTxHlm0LglBifa8CzJEm24tcrXNiRmPYSCgdCxlqFUylMmVAi-OB7lEx2-h5OiLOxHYCaySYSm2giliAlH-cJYTyaWa6V9ETjg7YSRmp63nNJnrNM943IrvxTll5L80nsHvu-7VB1px7HGg0cSPvSIeUwpUR242Ik87Td4ne6XowNf97W4M-m5RRW23NQpYmcZ8dh7ukXgCdSw_Mg_BJ4GJSpVBz50a-0wOoSSgZDBp6Oju4CX3Z0ROc19hpPmbmO_IIpq9KDdKwM4HU3G4xl-x9ez-e__yGIfWQ |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrQRICEF5hULrA_SANiJPJzkgVEqrLe2uVmgr9RZsxxErrZLQZEXDkf_Df2Qmj1310L31GDm2LH3j8Te25xuAd2GS2oGLzC1VQpleFApTpJ5lJp5Mhe9KqRud2fGEjy68b5f-5Rb863Nh6Fll7xMbR53kis7IP-JWROJo3P1c_DKpaBRdrvYVNFqrONP1b4zYyk-nXxHe945zcjw7GpldUQFTeXZYmbbmKgrSRKFbjhTar_KTKImk8rUWttQuacIhiXG4DGTohkJYQrkCaYOPQWgkXRz3Hmx7LkYyA9j-cjyZfl-7fo-yPtsPjtSj1YB2KYPND_s7VauRMHWoqgI9nHOCyLy-sSs-KkSJAKVtZY3bqW-zBZ48gccdd2WHrbE9hS2d7cD9cXc7vwMH01YHux6y2TqtqxyyAzZdK2TXz-AvNjNR1QVZCENs510yGP7NMNbO_ogCR8SWhOGU0AnR55DJZcWyvGI_xSInheYkXwzZFYnPanZ4NBs1HTCcrua4olhJjJjsjs0z1uZ71qxcSjp5Kp_DxZ3g9gIGWZ7pV8CUpyMPyYHiQpD2jrC50lYYaV8KaXPHAKsHI1adUjoV7FjEK43nBr8Y8YsJv_jagA-rLkUrE7Lp570bCK97BH5ARVgN2O0hjzuXUsarBWDA_qoVfQFd8IhM58syRrYeen5g3f6HY3H06f6GMTjGnyG6cQNetra2nh2SV4eHzuuNs9uHB6PZ-Dw-P52c7cLD9sSKnuy9gUF1tdRvkcNVcq9bOQx-3PVi_Q_Vx1se |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVICEGBEgqtD9AD2qh52UkOCFUtqy2l1R620t6C7ThipVUSmqzocuRf8e-YyWNXPXRvPVp-yNI8_I3t-QbgQ5Rmbugjcsu01HYQR9KWWeDYaaAyyX2lTMMze3klRtfBtymfbsG_PheGvlX2PrFx1Gmh6Y78GI8iIkcT_nHW_YoYnw2_lL9sKiBFD619NY1WQy7M8jdGb9Xn8zMU9UfPG36dnI7srsCArQM3qm3XCB2HWarRRccadVnzNE5jpbkx0lXGJ344BDSeUKGK_EhKR2pfIoTgGJDGysd1H8Hj0OcumVg4DdeHQED5n21DIAhp2aB9ymXjUf-66jRkph7VV6AvdF4Y27d3zsenpaxQVFlbY-N-ENwchsPn8KxDseykVbsXsGXyXdi57N7pd-Fo3DJiLwdssk7wqgbsiI3XXNnLl_AXu5mslyXpCkMpz7q0MBzNMOrO_8gSV8SelOGW0B1Rc8DUomZ5UbOfcl4QV3NazAfshmhoDTs5nYyaCRhY1zO0LVYRNiYNZLOctZmfS1YtFN1BVa_g-kGk9hq28yI3b4DpwMQBwgQtpCQWHukKbZwoNlxJ5QrPAqcXRqI7znQq3TFPVmzPjfwSlF9C8ktuLfi0mlK2hCGbBh_ckfB6RshDKsdqwX4v8qRzLlWyMgULDle96BXoqUfmplhUCeL2KOChc_8IzxHo3fmGNQRGohE6dAv2Wl1b7w5hrCci7-3G3R3CDppo8v386mIfnrRXV_R37x1s1zcL8x7BXK0OGrNh8OOh7fQ_FAZd7g |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+atypical+antipsychotics+olanzapine+and+quetiapine%2C+but+not+haloperidol%2C+reduce+ACTH+and+cortisol+secretion+in+healthy+subjects&rft.jtitle=Psychopharmacology&rft.au=Cohrs%2C+Stefan&rft.au=R%C3%B6her%2C+Cornelia&rft.au=Jordan%2C+Wolfgang&rft.au=Meier%2C+Andreas&rft.date=2006-03-01&rft.issn=0033-3158&rft.volume=185&rft.issue=1&rft.spage=11&rft_id=info:doi/10.1007%2Fs00213-005-0279-x&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon |